NephroPlus
MAINBOARD
Listed
Price Band
₹438 - ₹460
Lot Size
32 Shares
Issue Size
₹353.41 Cr
Fresh Issue
₹247.39 Cr
OFS
₹106.02 Cr
Registrar
KFin Technologies Limited
AI Sentiment Score
Listing Price
₹490.00
vs Issue: ₹460 (+6.52%)
📅 IPO Timeline
✓
Open
Dec 10, 2025
✓
Close
Dec 12, 2025
✓
Allotment
Dec 15, 2025
✓
Refund
Dec 16, 2025
✓
Demat
Dec 16, 2025
✓
Listing
Dec 17, 2025
📈 Grey Market Premium (GMP) Trendline
Daily consensus GMP movement (₹) recorded across market sources
✨ AI Analysis & Prediction
🔒 Final Reconciled Estimate
Locked post-listing with actual debut performance
NephroPlus displays an established operational footprint with expanding revenue streams (31.7% CAGR) and a defensible value proposition.
💪 Strengths
- Demonstrated operational revenue trajectory with resilient top-line growth (31.7% CAGR).
- Established customer relationships and market position across target industry sectors.
- Sound operational capital returns with Return on Capital Employed (ROCE) at 15.3%.
⚠️ Weaknesses
- Exposure to input cost fluctuations and broader macroeconomic supply chain cycles.
- Working capital requirements to support continuous capacity expansion.
- Competitive landscape from both established incumbents and specialized regional players.
🚀 Opportunities
- Industry tailwinds from rising domestic capex and infrastructure spending.
- Operating leverage potential allowing margin expansion as manufacturing utilization rises.
- Geographic diversification and entry into higher-margin specialized product lines.
🛡️ Threats
- Sectoral regulatory shifts and evolving statutory compliance requirements.
- Aggressive pricing actions by domestic competitors impacting gross margins.
- Broader market equity volatility and liquidity fluctuations.
📊 Financial Overview & Growth Trajectory
Multi-year operational scale & net profitability trajectory
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue (₹ Cr) | Rs 437.00 Cr | Rs 566.00 Cr | Rs 756.00 Cr | Rs 999.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs -12.00 Cr | Rs 35.00 Cr | Rs 67.00 Cr | Rs 77.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 49.00 Cr | Rs 101.00 Cr | Rs 167.00 Cr | Rs 225.00 Cr |
| Borrowings (₹ Cr) | Rs 200.00 Cr | Rs 271.00 Cr | Rs 261.00 Cr | Rs 80.00 Cr |
| Total Assets (₹ Cr) | Rs 666.00 Cr | Rs 806.00 Cr | Rs 994.00 Cr | Rs 1,467.00 Cr |
| ROE % | 0.00% | 0.00% | 0.00% | 0.00% |
| ROCE % | 15.30% | 15.30% | 15.30% | 15.30% |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 |
Company P/E
75.0x
Industry P/E
86.2x
Debt/Equity
0.07
⚖️ Valuation Benchmark Range
🟢 Attractively Priced vs Industry Peers
Industry 86.2x
IPO 75.0x
0x (Deep Value)
116x (High Multiple)
📋 Live Subscription Status
QIB
27.47x
NII
29.81x
Retail
2.31x
Total
13.96x
🎯 Retail Allotment Probability
43.3% Odds
1 in 2.3 chance (~43.3% probability per PAN)
SEBI Rule: Under SEBI lottery allotment rules, applying for multiple lots under Retail does NOT increase your lottery odds. All valid retail applicants have identical 1-lot odds per PAN.
Updated: Sep 12, 2026 2:33 PM
💼 Issue Structure & Reservation Quota
Capital Structure
₹353.4 Cr
Issue Size
Fresh (70%)
OFS (30%)
Reservation Quota
100%
Allocation
QIB (50%)
NII (15%)
Retail (35%)
QIB
50.00%
Retail
35.00%
NII
15.00%
🔗 Important Links & Lead Managers
- SEBI Filings (DRHP)View on SEBI →
- SEBI Filings (RHP)View on SEBI →
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.